Skip to content

iTeos Therapeutics, Inc.

CIK 0001808865

← back to feed
Revenue (TTM)
$35M
+177.9% YoY Q2 Jul 2025
Net Income (TTM)
−$165.83M
−19.3% YoY Q2 Jul 2025
EPS Diluted (TTM)
−$3.84
−5.4% YoY Q2 Jul 2025
Gross Margin
—
Q2 Jul 2025
Operating Margin
-533.6%
Q2 Jul 2025
Net Margin
-473.8%
Q2 Jul 2025
Free Cash Flow (TTM)
−$118.11M
Q2 Jul 2025
Cash
$207.82M
Q2 Jul 2025
Total Debt
—
Q2 Jul 2025
Shares Outstanding
44.21M sh
Q2 Jul 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings